Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03687242 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia
A Phase 2 study of Congenital Adrenal Hyperplasia and CAH - Congenital Adrenal Hyperplasia, sponsored by Spruce Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
- 8
- Study locations
NCT03687242 is a Phase 2 study of Congenital Adrenal Hyperplasia and CAH - Congenital Adrenal Hyperplasia that has completed, run by Spruce Biosciences. The registered enrollment target is 11 participants, below the 101-participant average among 8 other Congenital Adrenal Hyperplasia trials with a reported enrollment target (89% lower). The trial reports 8 study locations across 7 states.
The verdict
NCT03687242, a Phase 2 study of Congenital Adrenal Hyperplasia and CAH - Congenital Adrenal Hyperplasia, has completed, sponsored by Spruce Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a Phase 2 study of SPR001 for the treatment of classic CAH that will provide 12 weeks of open-label treatment to eligible subjects.
Conditions Studied
Interventions
- DRUG SPR001
Study Locations (8)
California
- Spruce Biosciences Clinical Site - Orange
- Spruce Biosciences Clinical Site - San Diego
Georgia
- Spruce Biosciences Clinical Site - Atlanta
Indiana
- Spruce Biosciences Clinical Site - Indianapolis
Michigan
- Spruce Biosciences Clinical Site - Ann Arbor
Minnesota
- Spruce Biosciences Clinical Site - Minneapolis
Nevada
- Spruce Biosciences Clinical Site - Las Vegas
Pennsylvania
- Spruce Biosciences Clinical Site - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2018-09-06 |
| Est. Completion | 2019-08-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03687242
The ClinicalTrials.gov registry entry for NCT03687242 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 101-participant average among 8 other Congenital Adrenal Hyperplasia trials with a reported enrollment target (89% lower). The listed sponsor is Spruce Biosciences, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Congenital Adrenal Hyperplasia appearing as the primary indexed condition, and to 1 intervention - of which SPR001 is the first listed.
NCT03687242 reports 8 study locations spanning 7 distinct geographic areas - top geographies include California, Georgia, Indiana.
Frequently Asked Questions
What is clinical trial NCT03687242 about?
NCT03687242 is a clinical study titled "Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia". This is a Phase 2 study of SPR001 for the treatment of classic CAH that will provide 12 weeks of open-label treatment to eligible subjects.
What is the current status of trial NCT03687242?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2018-09-06. Estimated completion is 2019-08-09.
What conditions does trial NCT03687242 study?
This clinical trial studies the following conditions: Congenital Adrenal Hyperplasia, CAH - Congenital Adrenal Hyperplasia, CAH - 21-Hydroxylase Deficiency.
What interventions are being tested in trial NCT03687242?
The interventions under investigation include: SPR001 (DRUG).
Who is sponsoring clinical trial NCT03687242?
This trial is sponsored by Spruce Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03687242 being conducted?
This trial has 8 study locations across California, Georgia, Indiana, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congenital Adrenal Hyperplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
RECRUITING · Phase 2
-
An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894
RECRUITING · Phase 2
-
A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia
RECRUITING · Phase 1
-
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
RECRUITING · Phase 3
-
A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH)
ACTIVE NOT RECRUITING · Phase 1
-
Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Congenital Adrenal Hyperplasia
All registered trials for this condition
CAH - Congenital Adrenal Hyperplasia
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.